Compare Becton Dickinson and Co (BDX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs State Street SPDR S&P Biotech ETF — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while State Street SPDR S&P Biotech ETF trades at $155.35. The key difference: Becton Dickinson and Co pays a 2.79% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Becton Dickinson and Co nearer its low. Which is the better fit depends on your goals.
| BDX | XBI | |
|---|---|---|
Market Cap | $41.51B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $185.39 | $164.28 |
52-Week Low | $135.49 | $85.16 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
XBI trades at $155.34, down 2.32% on the day, but maintains a bullish technical outlook with strong momentum indicators. The biotech ETF has gained significant attention after a 17% monthly surge, driven by sector rotation and M&A activity. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech's strong performance amid market volatility.
The ETF offers exposure to biotech's resurgence with AI drug discovery and deal momentum as catalysts. However, high volatility and concentrated sector risk require careful position sizing. Current technical strength suggests potential for continued upside if sector momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
